Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 1, 2020

BioPharm International

  • BioPharm International-07-01-2020
  • Volume 33
  • Issue 7

Pump Tubing System

AdvantaPure’s GORE STA-PURE Pump Tubing systems can now overmold into any manifold tubing assembly as its pump element.

AdvantaPure’s GORE STA-PURE Pump Tubing systems can now overmold into any manifold tubing assembly as its pump element. Designed for optimal performance in peristaltic pumps, the system is made with platinum-cured silicone rubber and ePTFE for a fluid transfer product that uses overmolding technology to provide a smooth contact surface for fluid flow.

The tubing system can also lessen the risk of tubing ruptures in pumps, withstand operating pressures up to 100 psig, maintain consistent flow rates, lower spallation, and support sterile fluid processing.

AdvantaPure




 


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.